Showing 1 - 8 results of 8 for search 'Scott Hoffmann', query time: 0.05s Refine Results
  1. 1
    Using predictions from multiple anthropogenic threats to estimate future population persistence of an imperiled species

    Using predictions from multiple anthropogenic threats to estimate future population persistence of an imperiled species by Brian Folt, Michael Marshall, Jo Anna Emanuel, Michelina Dziadzio, Jane Cooke, Lourdes Mena, Matthew Hinderliter, Scott Hoffmann, Nicole Rankin, John Tupy, Conor McGowan

    Published 2022-08-01
    Get full text
    Article
  2. 2
    scRNA Transcription Profile of Adult Zebrafish Podocytes Using a Novel Reporter Strain

    scRNA Transcription Profile of Adult Zebrafish Podocytes Using a Novel Reporter Strain by Cara Brown, Linda J. Mullins, Katrina Wesencraft, Gail McConnell, Mariana Beltran, Neil C. Henderson, Bryan Conway, Scott Hoffmann, Sebastian Rider, John J. Mullins

    Published 2021-05-01
    Get full text
    Article
  3. 3
    785 mAZD0171 mediated LIF blockade in combination with chemotherapy and PD-L1 inhibition repolarizes macrophages and increases T cell infiltration via CX3CR1-CX3CL1 axis

    785 mAZD0171 mediated LIF blockade in combination with chemotherapy and PD-L1 inhibition repolarizes macrophages and increases T cell infiltration via CX3CR1-CX3CL1 axis by Scott Hammond, Robert Wilkinson, Michal Sulikowski, Jean-Martin Lapointe, Gozde Kar, Jim Eyles, Scott Hoffmann, Nadia Luheshi, Juliana Candido, Grace Opoku-Ansah, Fabien Garcon, Chelsea Gerada, Bairu Zhang, Rakesh Choudhary, Douglas C Palmer, Stewart Jones

    Published 2023-11-01
    Article
  4. 4
    877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models

    877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in p... by Matthew King, Dmitry Gabrilovich, Simon Barry, Mark Cobbold, Viia Valge-Archer, Adina Hughes, Elizabeth Hardaker, Alison Peter, Anisha Solanki, Lukasz Magiera, Gozde Kar, Stephen Fawell, Ankur Karmokar, Marta Milo, Chrysiis Michaloglou, Ricardo Miragaia, Sara Talbot, Carolyn Lam, Daniel Sutton, Scott Hoffmann, Larissa Carnevalli, Zena Wilson, Alan Lau

    Published 2023-11-01
    Article
  5. 5
    Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

    Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models by Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza C. de Bruin, Simon T. Barry

    Published 2023-08-01
    Get full text
    Article
  6. 6
    Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

    Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models by Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza C. de Bruin, Simon T. Barry

    Published 2023-09-01
    Get full text
    Article
  7. 7
    Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

    Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models by Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza DeBruin, Simon T. Barry

    Published 2023-08-01
    Get full text
    Article
  8. 8
    The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

    The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment by Elizabeth L. Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa Carnevalli, Fernando J. Calero-Nieto, Gemma N. Jones, Andrew J. Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P. Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J. Carl Barrett, Arsene-Bienvenu Loembé, Serge Y. Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A. Nance, Carlos Alberto Gomez Roca, Elaine Cadogan, Susan E. Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I. Gabrilovich, Simon T. Barry

    Published 2024-02-01
    Get full text
    Article

Search Tools: